Notice of Intention to make an award under the Most Suitable Provider (MSP) process - Provision of end-to-end digital histopathology pathway service with integrated AI diagnostic support and NHS reporting services

1. This is a Provider Selection Regime (PSR) Notice of Intention to make an award. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. This is a Notice of Intention to make an award and is being published in line with Regulation 12 - under The Health Care Services (Provider Selection Regime - PSR) Regulations 2023. The Most Suitable Provider Process shall be used to commission this service and award a contract. 2. The contract title and Reference - Provision of end-to-end digital histopathology pathway service with integrated AI diagnostic support and NHS reporting The contract reference - C407455 3. The name and address of the registered office or principal place of business of the provider to whom the contract has been awarded - Inify Laboratories Ltd 191c Nebula Park Drive Milton Park Oxfordshire England OX14 4SE 4. A description of the relevant health care services to which the contract relates, including the most relevant CPV code - Inify delivers a fully integrated, co-designed diagnostic service that aligns with NHS pathways, enables seamless information sharing, and strengthens multidisciplinary collaboration. Its resilient, scalable, and digitally enabled model ensures long-term service continuity and robust governance 85111800 - Pathology services 5. The lifetime value of the contract or, where it is not known, the amounts payable to the provider under the contract - £275000 6. Details of the award decision-makers - Rob Archer (Cellular & Anatomical Pathology Operations Manager), Mark Austin (Category Manager for Clinical Support) 7. A statement explaining the award decision-makers’ reasons for selecting the chosen provider, with reference to the key criteria - Based on our assessment against PSR criteria, we believe Inify Laboratories is the only provider capable of delivering the required service for the following reasons: • End-to-End Integrated Diagnostic Pathway: Inify offers a fully digital, AI-supported histopathology service covering the entire prostate cancer diagnostic workflow—from biopsy logistics to final reporting—within a unified digital ecosystem. • Immediate Access to a Complete Digital Solution: Their platform is fully paperless and interoperable from day one, regardless of the Trust’s existing digital infrastructure. • Specialist Focus and Proven Expertise: Inify is purpose-built for prostate cancer diagnostics, with 2.5 years of proven experience in Sweden, delivering faster and more accurate diagnoses compared to generalist labs. • AI-Enhanced Accuracy and Efficiency: Validated AI tools significantly reduce diagnostic variation and improve turnaround times (average 3.5 days), supporting NHS reporting targets. • ISO 15189 Accredited Digital Lab: Inify operates a fully standardised, controlled laboratory with embedded AI and an in-house LIMS, ensuring quality and compliance at scale. • Alignment with NHS Objectives: The service directly supports the NHS Histopathology Improvement Plan and National Cancer reporting targets, while improving workforce efficiency and patient experience 8. Any declared conflicts or potential conflicts of interest - No declared conflicts of interest 9. Information as to how any conflicts or potential conflicts of interest were managed - Decision makers have completed and signed conflicts of interest declarations prior to commencing the process (no conflicts declared).